Skip to content

Author

Anastasija Cupic

We have 2 of 34 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jan 2026

A bireporter recombinant SARS-CoV-2 Omicron BA.5 for in vitro and in vivo studies

The results demonstrate the feasibility of using rBA.5 ZsG-Nluc to track viral infections and identify prophylactics and therapeutics against recent SARS-CoV-2 VoCs in vitro, ex vivo, and in vivo.

Esteban M. Castro, Ramya S. Barre, C. Ye et al. · 0 citations
Open access Aug 2026

Mutations in SARS-CoV-2 Nsp1 are critical determinants of viral pathogenicity in mice

The reduced pathogenicity of rSARS-CoV-2 Nsp1 mutants highlights the potential for targeting Nsp1 for rational design of viral inhibitors and development of live-attenuated vaccine strategies as effective prophylactic and therapeutic treatments to combat SARS-CoV-2 and possibly other CoV infections.

Nathaniel Jackson, Fu-Chun Zhou, Anastasija Cupic et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.